Notably, STAT3 activation is mainly driven by oncogenic KRAS mutation, found in ~95% of pancreatic intraepithelial neoplasias (PanINs), the earliest pre-neoplastic stages of PDA progression [13, 41, 42]. This evidence concerns the gene KRAS and Patent ductus arteriosus.